The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4 helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 11; p. 594735
Main Authors Liu, Taoming, Li, Sheng, Ying, Shuni, Tang, Shunli, Ding, Yuwei, Li, Yali, Qiao, Jianjun, Fang, Hong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.11.2020
Subjects
IL-17 family
IL-23
IL-23/IL-17 axis
Immunology
psoriasis
targeted therapy
IL-23/IL-17 axis
targeted therapy
IL-17 family
IL-23
psoriasis
Online AccessGet full text

Cover

More Information
Summary:Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4 helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. The IL-23/IL-17 axis is an important pathway for targeted therapy for inflammatory diseases. Emerging evidence from clinical trials has shown that monoclonal antibodies against IL-23, IL-17, and tumor necrosis factor are effective in the treatment of patients with psoriasis, atopic dermatitis, hidradenitis suppurativa, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Here, we summarize the latest knowledge about the biology, signaling, and pathophysiological functions of the IL-23/IL-17 axis in inflammatory skin diseases. The currently available biologics targeting the axis is also discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
Edited by: Matteo Vecellio, University of Oxford, United Kingdom
Reviewed by: Maddalena Napolitano, University of Molise, Italy; Gholamreza Azizi, Alborz University of Medical Sciences, Iran
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.594735